Trupharma and Harris would not have to add an additional $ to...

Trupharma and Harris would not have to add an additional $ to their organisation to market ACR's approved drugs, so first $ straight to their bottom line. Their business model is a portfolio play, so they will sign up dud's, however, any impact is derisked across their portfolio of drugs. If they pay any milestones on FDA approval that may indicate a sentiment of their view on the assets.
Amring as a co-development seems different as they are taking "skin in the game" early which represents risk but a greater slice of the pie later ?? According to the financial report the $300k was for ACR development costs incurred. ACR has stated that the development programs cost between $3-5mil, so a fairway to go for the Amring co-development.
I'm not sure cash will be ok, hope I'm wrong but it maybe managed by slowing down spending on development program which means delays to market.